InvestSMART

BlinkLab Limited (ASX:BB1)

ALERT: Price-sensitive ASX Announcement for BB1
Current share price for BB1 : $0.650 -0.015 (-2.26%)+
Announcement
Release
30 Apr 2026 8:39AM
Price at Release
$0.665
Full Release
download
Summary
BlinkLab Limited, a leader in digital healthcare, has made significant advancements in its operations for the quarter ending March 31, 2026. The company has successfully completed the onboarding of clinical sites for its pivotal FDA 510(k) study and has commenced validation with the first participant tested. Additionally, BlinkLab has launched a nationwide autism screening program in Morocco, showcasing its capability in large-scale deployments. The company also expanded its influence within the U.S. autism research ecosystem, engaging in strategic partnerships and gaining scientific credibility. Financially, BlinkLab reported a net cash usage of A$1.036 million for operations in the quarter, with significant funds raised post-quarter to support future growth initiatives.
Key Points
  • Onboarding of all Clinical Sites for Pivotal FDA Study completed.
  • First Participant Enrolled in FDA 510(k) Pivotal Validation.
  • Launch of Nationwide Autism Screening Program in Morocco.
  • Expansion of Clinical and Scientific Influence in the U.S.
  • Completion of a A$17.5M placement to institutional investors.
  • Financial activities included A$1.036 million net cash used in operations.
  • Cash balance at 31 March 2026 was A$4.319 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.